References
- King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. [Internet]. 2014;370(22):2083–2092. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24836312
- Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. [Internet]. 2014;370(22):2071–2082. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24836310
- Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. AJP Lung Cell Mol Physiol. [Internet]. 2010;298(6):L715–L731. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20363851
- Xu MY, Porte J, Knox AJ, et al. Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol. [Internet]. 2009;174:1264–1279. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2671359&tool=pmcentrez&rendertype=abstract
- Mercer PF, Woodcock HV, Eley JD, et al. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF. Thorax. [Internet]. 2016; thoraxjnl-2015-207429. Available from: http://thorax.bmj.com/content/early/2016/04/21/thoraxjnl-2015-207429?papetoc
- Leask A, Abraham DJ. TGF- signaling and the fibrotic response. FASEB J. [Internet]. 2004;18(7):816–827. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15117886
- Cruz FF, Horta LFB, De Albuquerque Maia L, et al. Dasatinib reduces lung inflammation and fibrosis in acute experimental silicosis. PLoS One. 2016;11(1):1–17.
- Cox N, Pilling D, Gomer RH. Serum amyloid P: a systemic regulator of the innate immune response. J Leukoc Biol. [Internet]. 2014;96(November):1–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24804675.
- Toonkel RL, Hare JM, Matthay MA, et al. Mesenchymal stem cells and idiopathic pulmonary fibrosis potential for clinical testing. Am J Respir Crit Care Med. 2013;188(2):133–140.
- Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir Med. [Internet]. 2014;2(11):933–942. DOI:10.1016/S2213-2600(14)70232-2.
- Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax. [Internet]. 2013;68:155–162. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23143842
- Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. [Internet]. 2002;110(6):673–687. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12297042
- Nho RS, Polunovsky V. Translational control of the fibroblast-extracellular matrix association: an application to pulmonary fibrosis. Transl (Austin, Tex.). [Internet]. 2013;1(1):e23934. Available from: http://www.tandfonline.com/doi/full/10.4161/trla.23934#.WIFAZMgpDhQ.mendeley
- Saini G, Porte J, Weinreb PH, et al. αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease. Eur Respir J. 2015;46(2):486–494. DOI:10.1183/09031936.00210414.
- Lo DJ, Farris AB, Song M, et al. Inhibition of αvβ6 promotes acute renal allograft rejection in nonhuman primates. Am J Transpl. 2013;13:3085–3093. DOI:10.1111/ajt.12467.
- Perrakis A, Moolenaar WH. Autotaxin: structure-function and signaling. J Lipid Res. [Internet]. 2014;55(6):1010–1018. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24548887
- Umezu-Goto M, Kishi Y, Taira A, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol. [Internet]. 2002;158:227–233. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12119361
- Tager AM, LaCamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med. [Internet]. 2008;14:45–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18066075
- Oikonomou N, Mouratis M-A, Tzouvelekis A, et al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol. [Internet]. 2012;47:566–574. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22744859
- Van Der Aar EM, Heckmann B, Blanque R, et al. Pharmacological profile and efficacy of GLPG1690, a novel autotaxin inhibitor for the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. [Internet]. 2016;193(A4532). Available from: http://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A4532
- Van Der Aar EM, Fagard L, Desrivot J, et al. Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. [Internet]. 2016;193(A2701). Available from: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A2701
- Blanque R, Desroy N, Dupont S, et al. Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment. Eur Respir J. 2015;46(suppl 59);2129.
- Neidlinger NA, Larkin SK, Bhagat A, et al. Hydrolysis of phosphatidylserine-exposing red blood cells by secretory phospholipase A2 generates lysophosphatidic acid and results in vascular dysfunction. J Biol Chem. [Internet]. 2006;281(2):775–781. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16278219
- Tager AM. Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis : limiting fibrosis by limiting lysophosphatidic acid synthesis. Am J Respir Cell Mol Biol. 2012;47(5):563–565.
- Choi JW, Herr DR, Noguchi K, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol. 2010;50:157–186. DOI:10.1146/annurev.pharmtox.010909.105753
- Watterson KR, Lanning DA, Diegelmann RF, et al. Regulation of fibroblast functions by lysophospholipid mediators: potential roles in wound healing. Wound Repair Regen. [Internet]. 2007;15(5):607–616. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17971005.
- Swaney J, Chapman C, Correa L, et al. A novel, orally active LPA 1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin modelb ph. Br J Pharmacol. 2010;160:1699–1713.
- Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene. [Internet]. 2001;20(19):2390–2400. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11402335
- Seimiya H, Mashima T, Toho M, et al. c-Jun NH2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J Biol Chem. [Internet]. 1997;272(7):4631–4636. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9020192
- Wygrecka M, Zakrzewicz D, Taborski B, et al. TGF-β1 induces tissue factor expression in human lung fibroblasts in a PI3K/JNK/Akt-dependent and AP-1-dependent manner. Am J Respir Cell Mol Biol. [Internet]. 2012;47:614–627. Available from: http://www.atsjournals.org/doi/abs/10.1165/rcmb.2012-0097OC
- Cui Y, Osorio J, Risquez C, et al. Transforming growth factor-β1 downregulates vascular endothelial growth factor-D expression in human lung fibroblasts via the Jun NH2-terminal kinase signaling pathway. Mol Med. [Internet]. 2014;20:120-134. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24515257
- Grimminger F, Schermuly RT, Ghofrani HA. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov. 2010;9(12):956–970. DOI:10.1038/nrd3297
- Kral JB, Kuttke M, Schrottmaier WC, et al. Sustained PI3K Activation exacerbates BLM-induced Lung Fibrosis via activation of pro-inflammatory and pro-fibrotic pathways. Sci Rep. [Internet]. 2016;6:23034. Available from: http://www.nature.com/srep/2016/160314/srep23034/full/srep23034.html
- Jin X, Dai H, Ding K, et al. Rapamycin attenuates bleomycin-induced pulmonary fibrosis in rats and the expression of metalloproteinase-9 and tissue inhibitors of metalloproteinase-1 in lung tissue. Chin Med J (Engl). [Internet]. 2014;127(7):1304–1309. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24709185
- Xu X, Wan X, Geng J, et al. Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase. Exp Biol Med. [Internet]. 2013;238(9):1082–1094. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23986222
- Xu X, Dai H, Geng J, et al. Rapamycin increases CCN2 expression of lung fibroblasts via phosphoinositide 3-kinase. Lab Investig. [Internet]. 2015;95:846–859. Available from: http://www.nature.com/doifinder/10.1038/labinvest.2015.68
- Street CA, Bryan BA. Rho kinase proteins–pleiotropic modulators of cell survival and apoptosis. Anticancer Res. [Internet]. 2011;31(11):3645–3657. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22110183
- Le -T-T-T, Karmouty-Quintana H, Melicoff E, et al. Blockade of IL-6 trans signaling attenuates pulmonary fibrosis. J Immunol. 2014;193(7):3755–3768.
- Lee JH, Zheng Y, Von Bornstadt D, et al. Selective ROCK2 inhibition in focal cerebral ischemia. Ann Clin Transl Neurol. Internet. 2014;1:2–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24466563
- Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. [Internet]. 2014;111(47):16814–16819. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25385601
- Pan LH, Yamauchi K, Uzuki M, et al. Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur Respir J. [Internet]. 2001;17:1220–1227. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11491168
- Bonniaud P, Kolb M, Galt T, et al. Smad3 null mice develop airspace enlargement and are resistant to TGF-beta-mediated pulmonary fibrosis. J Immunol. [Internet]. 2004;173:2099–2108. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15265946
- Allen JT, Knight RA, Bloor CA, et al. Enhanced insulin-like growth factor binding protein–related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol. [Internet]. 1999;21(6):693–700. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10572066
- Kono M, Nakamura Y, Suda T, et al. Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF). Clin Chim Acta. [Internet]. 2011;412:2211–2215. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21864521
- Raghu G, Scholand MB, De Andrade J, et al. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur Respir J. [Internet]. 2016;47(5):1481–1491. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26965296
- Tremblay M, Grouix B, Sarra-Bournet F, et al. Pbi-4050, A novel first-in-class anti-fibrotic compound, inhibits CTgf and collagen I production in human alveolar epithelial cells and fibroblasts, and reduces lung fibrosis in the bleomycin-induced lung fibrosis model. Am J Respir Crit Care Med. 2014;189:A1998.
- Königshoff M, Rojas M. Galectin-3: the bridge over troubled waters. Am J Respir Crit Care Med. [Internet]. 2012;185(5):473–475. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22383566
- Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. [Internet]. 2012;185:537–546. Available from: http://www.atsjournals.org/doi/abs/10.1164/rccm.201106-0965OC?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed#.WIExcLbHst0.mendeley
- Hirani N, Nicol L, MacKinnon AC, et al. TD139, a novel inhaled galectin-3 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). Results from the first in (IPF) patients study. QJM Int J Med. [Internet]. 2016;109:S16–S16. Available from: https://academic.oup.com/qjmed/article/109/suppl_1/S16/2565820/TD139-A-Novel-Inhaled-Galectin3-Inhibitor-for-The
- Rodriguez-Pascual F, Slatter DA. Collagen cross-linking: insights on the evolution of metazoan extracellular matrix. Scientific Reports 6, Article number: 37374 (2016). Available from: https://www.nature.com/articles/srep37374.
- Hinz B. Mechanical aspects of lung fibrosis: a spotlight on the myofibroblast. Proc Am Thorac Soc. 2012;9(3):137–147.
- Wipff PJ, Rifkin DB, Meister JJ, et al. Myofibroblast contraction activates latent TGF-??1 from the extracellular matrix. J Cell Biol. 2007;179(6):1311–1323.
- Chien JW, Richards TJ, Gibson KF, et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J. 2014;43(5):1430–1438.
- Raghu G, Brown KK, Collard HR, et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respir Med. [Internet]. 2016;2600(16):1–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27939076%0Ahttp://linkinghub.elsevier.com/retrieve/pii/S2213260016304210
- Meyer KC. Great expectations for simtuzumab in IPF fall short. Lancet Respir Med. [Internet]. 2017;5(1):2–3. Available from: http://linkinghub.elsevier.com/retrieve/pii/S2213260016304209
- Germain RN, Stefanová I. The dynamics of T cell receptor signalin: complex orchestration and the key roles of tempo and cooperation. Annu Rev Immunol. [Internet]. 1999;17:467–522. DOI:10.1146/annurev.immunol.17.1.467.
- Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Cell. 2008;111(3):1366–1377.
- Finn RS, Bengala C, Ibrahim N, et al. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res. Internet. 2011;17:6905–6913. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22028489
- Yilmaz O, Oztay F, Kayalar O. Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice. Growth Factors. [Internet]. 2015;33(5–6):366–375. Available from: http://www.tandfonline.com/doi/full/10.3109/08977194.2015.1109511
- Murota K, Terao J. Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolism. Arch Biochem Biophys. 2003;417(1):12–17.
- Wei Q-F, Wang X-H, Zhang X-Y, et al. Therapeutic effects of quercetin on bleomycin induced pulmonary fibrosis in rats. Int J Clin Exp Med. [Internet]. 2016;9:5161–5167. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16887060
- Murata T, Obiri NI, Puri RK. Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review). Int J Mol Med. 1998;1(3):551–557.
- Park S-W, Ahn M-H, Jang HK, et al. Interleukin-13 and its receptors in idiopathic interstitial pneumonia: clinical implications for lung function. J Korean Med Sci. [Internet]. 2009;24:614. Available from: https://synapse.koreamed.org/DOIx.php?id=10.3346/jkms.2009.24.4.614
- Lee CG, Homer RJ, Zhu Z, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J Exp Med. 2001;194(6):809-821.
- Murray LA, Zhang H, Oak SR, et al. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am J Respir Cell Mol Biol. Internet. 2014;50:985–994. Available from: http://www.atsjournals.org/doi/abs/10.1165/rcmb.2013-0342OC
- Clarke DL, Murray LA, Crestani B, et al. Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis? Pharmacol Ther. [Internet]. 2017;169:35–46. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0163725816301668
- Maes T, Joos GF, Brusselle GG. Targeting interleukin-4 in asthma: lost in translation? Am J Respir Cell Mol Biol. Internet. 2012;47(3):261–270. Available from: http://www.atsjournals.org/doi/abs/10.1165/rcmb.2012-0080TR
- Parra ER, Teodoro WR, Velosa APP, et al. Interstitial and vascular type V collagen morphologic disorganization in usual interstitial pneumonia. J Histochem Cytochem. 2006;54(12):1315–1325.
- Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest. [Internet]. 2007;117:3498–3506. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17965778
- Vittal R, Mickler EA, Fisher AJ, et al. Type V Collagen induced tolerance suppresses collagen deposition, TGF-Î2 and associated transcripts in pulmonary fibrosis. PLoS One. 2013;8(10):e76451.
- Wilkes DS, Chew T, Flaherty KR, et al. Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1393-1402.
- Pillling D, Roife D, Wang M, et al. Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol. 2007;179(6):4035–4044.
- Murray LA, Rosada R, Moreira AP, et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One. 2010;5(3):e9683.
- Dillingh MR, Van Den Blink B, Moerland M, et al. Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis. Pulm Pharmacol Ther. [Internet]. 2013;26:672–676. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23380438
- Van Den Blink B, Dillingh MR, Ginns LC, et al. Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. Eur Respir J. 2016;47(3):889–897. DOI:10.1183/13993003.00850-2015.
- Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med. [Internet]. 2007;357(18):1841–1854. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMra071371
- Wilborn J, Bailie M, Coffey M, et al. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest. [Internet]. 1996;97(8):1827–1836. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8621765
- Izumo T, Kondo M, Nagai A. Effects of a leukotriene B4 receptor antagonist on bleomycin-induced pulmonary fibrosis. Eur Respir J. 2009;34(6):1444–1451.
- Xue J, Kass DJ, Bon J, et al. Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients. J Immunol. [Internet]. 2013;191:2089–2095. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23872052
- Daoussis D, Liossis S-NC, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. [Internet]. 2012;30:S17–S22. Available from: https://www.socprox.net/login?url=http://search.proquest.com/professional/docview/1114940187?accountid=138535%5Cnhttp://www.clinexprheumatol.org/article.asp?a=4752
- Jordan S, Distler JHW, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. [Internet]. 2015;74:1188–1194. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24442885
- Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19(3):353–359.
- Donahoe M, Valentine VG, Chien N, et al. Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis. PLoS One. 2015;10(6):1–17.
- Ghadiri M, Young PM, Traini D. Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease. Expert Opin Biol Ther. Internet. 2016;16(3):375–387. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26593230
- Serrano-Mollar A, Nacher M, Gay-Jordi G, et al. Intratracheal transplantation of alveolar type II cells reverses bleomycin-induced lung fibrosis. Am J Respir Crit Care Med. 2007;176(12):1261–1268.
- Banerjee ER, Laflamme MA, Papayannopoulou T, et al. Human embryonic stem cells differentiated to lung lineage-specific cells ameliorate pulmonary fibrosis in a xenograft transplant mouse model. PLoS One. 2012;7(3):e33165.
- Barczyk M, Schmidt M, Mattoli S. Stem cell-based therapy in idiopathic pulmonary fibrosis. Stem Cell Rev Reports. Internet. 2015;11(4):598–620. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25896401
- Tzouvelekis A, Koliakos G, Ntolios P, et al. Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal. J Transl Med. 2011;9:182.
- Tzouvelekis A, Paspaliaris V, Koliakos G, et al. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med. 2013;11(1):1.
- Reddy M, Fonseca L, Gowda S, et al. Human adipose-derived mesenchymal stem cells attenuate early stage of bleomycin induced pulmonary fibrosis: comparison with pirfenidone. Int J Stem Cells. [Internet]. 2016;9(2):192–206. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27871152
- Chambers DC, Enever D, Ilic N, et al. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. Respirology. 2014;19(7):1013–1018.
- Silva JD, Paredes BD, Araújo IM, et al. Effects of bone marrow–derived mononuclear cells from healthy or acute respiratory distress syndrome donors on recipient lung-injured mice. Crit Care Med. [Internet]. 2014;42:e510–e524. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24633189
- Glassberg MK, Minkiewicz J, Toonkel RL, et al. Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): a phase I, safety, clinical trial. Chest. 2016. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27890713%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/27890713
- Oksenberg D, Dufu K, Patel MP, et al. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 2016;175(1):141–153.
- Geng X, Dufu K, Hutchaleelaha A, et al. Increased hemoglobin – oxygen affinity ameliorates bleomycin-induced hypoxemia and pulmonary fibrosis. Physiol Rep. 2016; 4(17): e12965.
- Molyneaux PL, Cox MJ, Willis-Owen SAG, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;190(8):906–913.
- Han MLK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014;2(7):548-556.
- Molyneaux PL, Cox MJ, Wells AU, et al. Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir Res. 2017;18(1):29.
- Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax. 2013;68(9):884–885.
- Raghu G, Meyer KC. Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy? Eur Respir J. [Internet]. 2012;39(2):242–245. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22298612
- King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. Internet. 2011;378(9807):1949–1961. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21719092
- Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–e19.
- Raghu G, Morrow E, Collins BF, et al. Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre. Eur Respir J. [Internet]. 2016;48:826–832. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27492835
- Canestaro WJ, Forrester SH, Raghu G, et al. Drug treatment of idiopathic pulmonary fibrosis systematic review and network meta-analysis. Chest. 2016;149(3):756–766.
- Lehtonen ST, Veijola A, Karvonen H, et al. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respir Res. [Internet]. 2016;17:14. Available from: http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=19&SID=2FwF7Ha8djsDUPRp1Bz&page=2&doc=12
- Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. [Internet]. 2015;45(5):1382–1392. Available from: http://erj.ersjournals.com/content/45/5/1382
- Nathan SD, Shlobin OA, Ahmad S, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration. 2008;76(3):288–294.
- Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010;363(7):620–628.
- Han MK, Bach DS, Hagan PG, et al. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest. 1699–1708;143(6):2013.
- Horn A, Palumbo K, Cordazzo C, et al. Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum. 2012;64(8):2724–2733.
- Yonemaru M, Kasuga I, Kusumoto H, et al. Elevation of antibodies to cytomegalovirus and other herpes viruses in pulmonary fibrosis. Eur Respir J. [Internet]. 1997;10:2040–2045. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9311499
- Tang Y-W, Johnson JE, Browning PJ, et al. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol. [Internet]. 2003;41:2633–2640. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12791891
- Lawson WE, Crossno PF, Polosukhin VV, et al. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. AJP Lung Cell Mol Physiol. [Internet]. 2008;294:L1119–L1126. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18390830
- Ebrahimi B, Dutia BM, Brownstein DG, et al. Murine Gammaherpesvirus-68 infection causes multi-organ fibrosis and alters leukocyte trafficking in Interferon-γ receptor knockout mice. Am J Pathol. [Internet]. 2001;158(6):2117–2125. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11395389
- Lok SS, Haider Y, Howell D, et al. Murine gammaherpes virus as a cofactor in the development of pulmonary fibrosis in bleomycin resistant mice. Eur Respir J. [Internet]. 2002;20(5):1228–1232. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12449178
- Pulkkinen V, Salmenkivi K, Kinnula VL, et al. A novel screening method detects herpesviral DNA in the idiopathic pulmonary fibrosis lung. Ann Med. [Internet]. 2012;44:178–186. Available from: http://www.tandfonline.com/doi/full/10.3109/07853890.2010.532151
- Varney VA, Parnell HM, Salisbury D, et al. A double blind randomised placebo controlled pilot study of oral co-trimoxazole in advanced fibrotic lung disease. Pulm Pharmacol Ther. [Internet]. 2008;21(1):178–187. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17500020
- Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. [Internet]. 2011;183:788–824. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21471066
- Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. AJP Lung Cell Mol Physiol. [Internet]. 2007;294(2):L152–L160. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17993587
- Costabel U, Crestani B, Wells AU, editors. Idiopathic pulmonary fibrosis [Internet]. European Respiratory Society. ERS Monograph. 2016. Available from: http://erspublications.com/lookup/doi/10.1183/2312508X.erm7116
- Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33-41.
- Richeldi L, Collard HRJM. Idiopathic pulmonary fibrosis. Lancet. [Internet]. 2017;S0140-6736((17)30866-8). Available from: https://www.karger.com/?doi=10.1159/000475780
- Collard HR, Bradford WZ, Cottin V, et al. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. Eur Respir J. [Internet]. 2015;46:243–249. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25900377
- Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence — what is it and what can it tell us? N Engl J Med. [Internet]. 2016;375:2293–2297. Available from: http://www.nejm.org/doi/10.1056/NEJMsb1609216
- Maher TM, Braybrooke R, Costa MJ, et al. The PROFILE (prospective observation of fibrosis in the lung clinical endpoints) study. Am J Respir Crit Care Med. [Internet]. 2017;195(A6790). Available from: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A6790
- Kusko RL, Brothers J, Liu G, et al. Comprehensive genomic profiling of the lung transcriptome in emphysema and idiopathic pulmonary fibrosis using RNA-Seq. BMC Proc. [Internet]. 2012;6:P21. Available from: http://bmcproc.biomedcentral.com/articles/10.1186/1753-6561-6-S6-P21
- Russell A-M, Sprangers MA, Wibberley S, et al. The need for patient-centred clinical research in idiopathic pulmonary fibrosis. BMC Med. [Internet]. 2015;13(1):240. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26399318
- Russell A-M, Ripamonti E, Vancheri C. Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients’ perspectives of the disease and treatment. BMC Pulm Med. 2016;16(10):1–7. DOI:10.1186/s12890-016-0171-y.
- Swigris JJ, Wilson SR, Green KE, et al. Development of the ATAQ-IPF: a tool to assess quality of life in IPF. Health Qual Life Outcomes. [Internet]. 2010;8(1):77. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20673370
- Poveda A, Martinez V, Serrano C, et al. SEOM Clinical Guideline for gastrointestinal sarcomas (GIST). Clin Transl Oncol. 2016; 18(12): 1221–1228.
- Oldham JM, Noth I. Idiopathic pulmonary fibrosis: early detection and referral. Respir Med. 2014;108(6):819-829.